Boji Medical Technology Co.Ltd(300404) 4 on April 1, the company said that its clinical business had been transformed from generic drugs to innovative drugs since the beginning of 2017. Innovative drugs account for more than half of the company’s new orders, and the order amount of generic drugs is declining. Among the major clinical projects in phase I, II and III, the number of innovative drug projects accounts for more than 70%. The company believes that the general direction of new drug research and development in the future is innovative drugs. Cro company must face the process of transformation from generic drugs to innovative drugs, and the company has basically completed the transformation.
© China Stock Market News